Find in Library

Current phase 3 trials for the treatment of non-alcoholic steatohepatitis (NASH) are discussed in this review. Modalities that are based on weight loss include therapeutic lifestyle changes, pharmacological weight loss drugs (e.g., orlistat), and bariatric surgery. Traditionally, insulin resistance has been targeted using pioglitazone, but liraglutide and elafibranor are emerging as potential treatments. With regard to the farnesoid X receptor (FXR) pathway, obeticholic acid has been approved for primary biliary cholangitis and is being studied as a treatment for NASH. Antioxidants include vitamin E and statins. Medications that target fibrogenesis directly instead of NASH include selonsertib. Keywords: Non-alcoholic fatty liver disease (NAFLD), Non-alcoholic steatohepatitis (NASH), Sleeve gastrectomy, Liraglutide, Obeticholic acid